All Pharmaceutical industry articles
View all stories with this category.
-
OpinionPutting combustion into reverse
Unburning carbon dioxide economically and at scale is a tough problem, but potentially world-changing
-
Business
Industry tightens emissions reduction targets
As COP26 approaches, many firms are announcing ambitious climate goals. But are they achievable?
-
Article
Kathleen Culhane Lathbury – an industrial pioneer
Nina Notman tells the story of the interwar industrial chemist whose analytical skill and persistence saw her outmanoeuvre sexism and prove her research aptitude
-
Opinion
Opening up a cellular black box
Working out how biomolecular condensates work may reveal a lot about the success or failure of different drugs
-
Business
Sartan contaminant recall hits generics manufacturers
Three European suppliers recalling multiple batches of medicines owing to active ingredient contamination
-
Business
US judge rules against GSK in trade secrets dispute
Firm will not receive compensation for claimed loses of over $1bn from theft of confidential information by two former scientists
-
Business
BMS and Eisai agree antibody-drug conjugate commercialisation deal
Companies will jointly develop cancer treatment, with BMS paying up to $3 billion for shared rights
-
Business
Regeneron’s Covid-19 antibodies help those who can’t make their own
Regn-Cov2 reduces deaths and shortens hospitalisation for these patients, even when given at late stages of infection
-
Business
Alzheimer’s antibody gets surprise US approval
Good news for industry and future drug approvals, but physicians doubt it will be effective for most patients
-
Research
Protein impurities found in AstraZeneca’s Covid-19 vaccine stir debate
Compounds might cause side effects but are unlikely to be behind extremely rare blood-clotting events
-
Business
Morphosys agrees to buy cancer epigenetics specialist Constellation
$1.7bn deal will be funded by selling rights to royalties on existing drugs
-
Business
US supreme court will not hear J&J talc appeal
Decision means J&J must pay $2.1 billion previously awarded to 22 women who say talc caused their ovarian cancer
-
Webinar
The age of digital chemistry
Join us to learn how data can solve existing bottlenecks in synthetic chemistry and why data analysis demands a multidisciplinary approach
-
Business
Striving to bolster the antibiotic pipeline before it becomes the next crisis
It’s been almost 10 years since the world was warned of a post-antibiotic apocalypse. Katrina Megget takes a look at the initiatives trying to support antimicrobial R&D
-
Business
US supreme court ends Sandoz–Amgen biosimilar dispute
Sandoz’s copy of arthritis drug Enbrel won’t be available in the US until 2029, 30 years after it was first marketed
-
Opinion
The side effects of being unique
Even the largest clinical trials won’t capture all possible bad reactions to a drug – we need pharmacovigilance
-
Webinar
A recipe for success in exploiting machine learning and data science
Join us to discover how data science and big data are revolutionising decision making – and why claims that experts are no longer needed are misleading
-
Webinar
Statistics versus machine learning: should we all learn artificial intelligence?
Join us to understand the limitations of deep learning & why advanced statistical modelling is still needed – both in academic curricula and in the toolbox of any scientist or engineer
-
Sponsored
Unlocking the future of medicines manufacturing with digital innovations
The Medicines Manufacturing Innovation Centre promises to revolutionise how we formulate, trial and produce medicines
-
Business
Antibody–drug conjugates drive growth in oncology
Antibody–drug conjugates are coming of age and pharma is investing, reports Katrina Megget
